U.S. Food and Drug Administration (OPDP / CBER Advertising and Promotional Labeling Branch) · United States
FDA Rx Promotion - Fair Balance of Benefit and Risk
Promotion must present risk information with prominence and readability reasonably comparable to the benefit claims and must not bury, shrink or visually minimize risks.
What is FDA Rx Promotion - Fair Balance of Benefit and Risk?
Promotion must present risk information with prominence and readability reasonably comparable to the benefit claims and must not bury, shrink or visually minimize risks. Apply to prescription drug ads, web pages, emails, social posts, videos and HCP pieces that contain benefit claims and risk information.
general_audience, general_adults_18plus, customers, health_professionals, patients · Prescription Drug · pharma
Where does this rule apply?
United States
Which marketing channels are covered?
all_channels
When does this rule take effect?
2026-10-07
What does this rule require?
Promotion must present risk information with prominence and readability reasonably comparable to the benefit claims and must not bury, shrink or visually minimize risks.
How can marketing teams comply?
Apply to prescription drug ads, web pages, emails, social posts, videos and HCP pieces that contain benefit claims and risk information.
What is FDA Rx Promotion - Fair Balance of Benefit and Risk?
Promotion must present risk information with prominence and readability reasonably comparable to the benefit claims and must not bury, shrink or visually minimize risks.
Who does this rule apply to?
general_audience, general_adults_18plus, customers, health_professionals, patients · Prescription Drug · pharma
On character-limited platforms (paid search, short posts, SMS), a prescription drug benefit claim should be accompanied in the same unit by the established name, the most serious risks and a direct link to complete risk information, or the claim should not be made there.
Consumer-directed TV, radio and streaming ads for prescription drugs must include a major statement of the major risks presented in a clear, conspicuous and neutral manner (consumer-friendly language, audio as clear as the rest of the ad, concurrent text on TV, no distractions), plus adequate provision for full labeling.
Promotion may not represent or suggest that a prescription drug is safer or has fewer or less serious risks than shown in its labeling, including by minimizing warnings and precautions.
A reminder piece may skip risk information only if it calls attention to the product name with permitted factual items and no representations, and reminders are not available for drugs with a boxed warning.
Unbranded disease-awareness pieces are outside the risk-disclosure rules only while they do not identify or suggest a specific product; brand cues, single-product category claims or a direct bridge to branded content make them promotion.
FDA recommends that consumer-directed prescription drug promotion stating efficacy or risk numbers give absolute frequencies for the drug and control groups, use consistent formats, and avoid relative-only figures that overstate benefit.
Request a free compliance scan of your homepage and book a time with Warrant.